Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2016 01:43 ET | Source: Genmab A/S

Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis

Company Announcement Phase III trials (ASCLEPIOS I and II) with the subcutaneous formulation of ofatumumab in Relapsing Multiple Sclerosis Studies expected to begin enrolling in September...
June 02, 2016 01:43 ET | Source: Genmab A/S

Genmab offentliggør fase III studier med ofatumumab til behandling af recidiverende multipel sklerose

Selskabsmeddelelse Fase III studier (ASCLEPIOS I og II) med den subkutane formulering af ofatumumab til behandling af recidiverende multipel sklerose Indrullering af patienter til...
May 31, 2016 11:05 ET | Source: Genmab A/S

Genmab’s Total Number of Voting Rights and Total Share Capital

Copenhagen, Denmark; May 31, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announces that pursuant to section 10 of Executive Order no. 1258 of November 9, 2015 on Issuers' Disclosure Obligations, the...
May 31, 2016 11:05 ET | Source: Genmab A/S

Genmabs samlede antal stemmerettigheder og samlede aktiekapital

København, Danmark, 31. maj 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) skal i henhold til § 10 i bekendtgørelse nr. 1258 af 9. november 2015 om udstederes oplysningsforpligtelser hermed meddele, at...
May 31, 2016 03:16 ET | Source: Genmab A/S

Genmab to Present at the Goldman Sachs 37th Annual Global Healthcare Conference

Media Release Copenhagen, Denmark; May 31, 2016 – Genmab A/S (OMX: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 37th Annual...
May 31, 2016 03:16 ET | Source: Genmab A/S

Genmab præsenterer ved den 37. årlige Goldman Sachs Global Healthcare konference

Pressemeddelelse København, Danmark, 31. maj 2016 – Genmab A/S (OMX: GEN) offentliggjorde i dag, at selskabets CEO, Jan van de Winkel, ph.d., vil give en præsentation om Genmab ved den 37. årlige...
May 30, 2016 10:56 ET | Source: Genmab A/S

Genmab når milestone på USD 30 mio. i samarbejdet med Janssen om DARZALEX® (daratumumab)

Selskabsmeddelelse Genmab vil modtage milestonebetaling fra Janssen på USD 30 mio. Milestone er udløst af det første kommercielle salg af DARZALEX i Europa København, Danmark; 30. maj...
May 30, 2016 10:56 ET | Source: Genmab A/S

Genmab Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collaboration with Janssen

Company Announcement Genmab to receive USD 30 million milestone payment from Janssen Milestone triggered by first commercial sale of DARZALEX in Europe Copenhagen, Denmark; May 30, 2016...
May 23, 2016 06:49 ET | Source: Genmab A/S

Genmab meddeler, at der er opnået betinget markedsføringstilladelse i Europa for DARZALEX® (daratumumab) til behandling af myelomatose

Selskabsmeddelelse DARZALEX (daratumumab) opnår betinget markedsføringstilladelse i Europa til behandling af patienter, som har fået adskillige tidligere behandlinger, eller som har...
May 23, 2016 06:49 ET | Source: Genmab A/S

Genmab Announces European Conditional Marketing Authorization for DARZALEX® (daratumumab) for Multiple Myeloma

Company Announcement DARZALEX (daratumumab) receives European conditional marketing authorization for heavily pre-treated or double refractory multiple myeloma First CD38 monoclonal...